Provided by Tiger Trade Technology Pte. Ltd.

SKB BIO

472.200
-14.800-3.04%
Volume:349.28K
Turnover:164.29M
Market Cap:112.86B
PE:-285.00
High:500.000
Open:500.000
Low:459.000
Close:487.000
52wk High:581.000
52wk Low:339.600
Shares:239.00M
HK Float Shares:177.00M
Volume Ratio:0.70
T/O Rate:0.20%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.657
ROE:2.92%
ROA:-0.04%
PB:18.08
PE(LYR):-285.00
PS:46.25

Loading ...

Movement Alert|Kelun-Biotech Rises 8.39% in Regular Trading, ASCO Phase III Data Continues to Catalyze Amid Biotech Sector Rally

Market Focus
·
Jul 02

Sichuan Kelun-Biotech Subscribes to Wealth Management Products

MT Newswires Live
·
Jul 01

SKB BIO Places Additional RMB600 Million in Principal-Guaranteed Structured Deposits; Wealth-Management Exposure Rises to RMB1.49 Billion

Bulletin Express
·
Jun 30

SKB BIO Allocates 600 Million Yuan for Structured Deposit Investments

Stock News
·
Jun 30

Sichuan Kelun-biotech Biopharmaceutical Co - Subscribes for Czb Structured Deposit V of Rmb200 Mln on June 30, 2026

THOMSON REUTERS
·
Jun 30

Movement Alert|Kelun-Biotech Biopharmaceutical Rises 4.04% in Regular Trading, Multiple Brokerages Upgrade Ratings Following ASCO Phase III Data

Market Focus
·
Jun 30

Asian Market's Hidden Gems: 3 Stocks That Might Be Trading Below Fair Value

Simply Wall St.
·
Jun 30

Kelun-Biotech AGM Clears All 2025 Financials, Re-appoints KPMG and Renews Capital Mandates

Bulletin Express
·
Jun 29

Movement Alert|Kelun-Biotech Rises 7.18% in Regular Trading, ASCO Landmark Data Continues to Drive Momentum Alongside Sector Rally

Market Focus
·
Jun 29

Movement Alert|Kelun-Biotech Falls 3.08% in Regular Trading, Trading at 411.4 HKD

Market Focus
·
Jun 25

Movement Alert|Kelun-Biotech Rises 7.44% in Regular Trading, ASCO Phase III Lung Cancer Data Catalyzes Overseas Commercialization Expectations

Market Focus
·
Jun 24

SKB BIO Shares Surge Over 6% on Key ASCO Lung Cancer Data, sac-TMT Nears Global Commercialization

Stock News
·
Jun 24

Movement Alert|Kelun-Biotech Rises 3.16% in Regular Trading, Biotech Sector Broadly Rallies Amid Positive Analyst Coverage

Market Focus
·
Jun 23

Kelun-Biotech says Phase III trial tests sac-TMT plus osimertinib in first-line EGFR-mutant NSCLC

Reuters
·
Jun 22

Movement Alert|Kelun-Biotech Falls 3.7% in Regular Trading, Biotech Sector Broadly Under Pressure

Market Focus
·
Jun 22

Industrial Securities Initiates Coverage on SKB BIO with "Overweight" Rating Following Key ASCO Lung Cancer Data Release

Stock News
·
Jun 18

Movement Alert|Kelun-Biotech Rises 3.03% in Regular Trading, RMB 703 Million Settlement Payment from Yilian Bio Continues to Catalyze

Market Focus
·
Jun 15

Innovative Drug Stocks See Broad Gains as Sector's Outbound Licensing Activity Remains Robust, Supported by Policy Tailwinds and Commercialization Progress

Stock News
·
Jun 12

Sichuan Kelun-Biotech Receives Nearly 603 Million Yuan From MediLink

MT Newswires Live
·
Jun 12

Movement Alert|Kelun-Biotech Rises 7.35% in Regular Trading, Receives RMB 7.03 Billion Settlement Payment from Yilian Biopharmaceutical

Market Focus
·
Jun 12